Stada Arzneimittel Aktiengesellschaft Stock Revenue
STADA Arzneimittel Aktiengesellschaft fundamentals help investors to digest information that contributes to STADA Arzneimittel's financial success or failures. It also enables traders to predict the movement of STADA OTC Stock. The fundamental analysis module provides a way to measure STADA Arzneimittel's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to STADA Arzneimittel otc stock.
STADA |
STADA Arzneimittel Aktiengesellschaft OTC Stock Revenue Analysis
STADA Arzneimittel's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current STADA Arzneimittel Revenue | 2.69 B |
Most of STADA Arzneimittel's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, STADA Arzneimittel Aktiengesellschaft is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, STADA Arzneimittel Aktiengesellschaft reported 2.69 B of revenue. This is 64.73% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 71.49% higher than that of the company.
STADA Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses STADA Arzneimittel's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of STADA Arzneimittel could also be used in its relative valuation, which is a method of valuing STADA Arzneimittel by comparing valuation metrics of similar companies.STADA Arzneimittel is currently under evaluation in revenue category among related companies.
STADA Fundamentals
| Return On Equity | 22.55 | |||
| Return On Asset | 6.39 | |||
| Profit Margin | 9.00 % | |||
| Current Valuation | 6.87 B | |||
| Shares Outstanding | 62.26 M | |||
| Shares Owned By Institutions | 0.30 % | |||
| Price To Earning | 22.46 X | |||
| Price To Book | 4.54 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 2.69 B | |||
| Gross Profit | 1.37 B | |||
| EBITDA | 559.98 M | |||
| Net Income | 252.03 M | |||
| Cash And Equivalents | 502.02 M | |||
| Cash Per Share | 8.06 X | |||
| Total Debt | 1.73 B | |||
| Debt To Equity | 2.58 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 20.02 X | |||
| Cash Flow From Operations | 347.14 M | |||
| Earnings Per Share | 4.05 X | |||
| Number Of Employees | 12.34 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 6.87 B | |||
| Total Asset | 3.46 B | |||
| Retained Earnings | 686 M | |||
| Working Capital | 604 M | |||
| Current Asset | 1.49 B | |||
| Current Liabilities | 887 M | |||
| Z Score | 1.8 | |||
| Last Dividend Paid | 0.11 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the STADA Arzneimittel information on this page should be used as a complementary analysis to other STADA Arzneimittel's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in STADA OTC Stock
If you are still planning to invest in STADA Arzneimittel check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the STADA Arzneimittel's history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |